datopotamab deruxtecan

targets

all catalysts(0)

nothing on the calendar yet

News(10)

• Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
  Plus news about Regeneron. Summit Therapeutics to test cancer drug with Datroway: The biotech agreed to partner with AstraZeneca and Daiichi Sankyo on a clinical trial collaboration, testing its Tr…
  endpoints · 1d ago
• AstraZeneca’s newly approved pill fails frontline breast cancer study
  Etcamah is the second oral “SERD” to recently fall short in first-line breast cancer, following a similar setback from Roche earlier this year.
  biopharma_dive · 19d ago
• BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
  BioNTech has linked gotistobart to a median overall survival of 18.5 months in relapsed lung cancer patients, adding to evidence that the anti-CTLA-4 antibody is better than the standard of care.
  fiercebiotech · 22d ago
• As portfolio erodes, BMS stands to gain a lot from rumored AstraZeneca merger
  While both drugmakers face looming patent cliffs, analysts say joining forces could help Bristol Myers Squibb replenish its eroding portfolio—while the strategic case for AstraZeneca seems to be mo…
  biospace · 2mo ago
• ‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
  If AstraZeneca and Bristol Myers Squibb were to successfully become one company, analysts say it could reset the current deal environment, which has picked up greatly in the first half of the year.
  biospace · 2mo ago
• Editor’s Corner: Why an AstraZeneca-Bristol Myers Squibb merger is a bad idea
  Combining the two drugmakers would trigger severe regulatory concerns and significant pipeline disruptions, cost numerous jobs, all while damaging the broader biopharma ecosystem and hurting patien…
  fiercebiotech · 2mo ago
• Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
  With Enhertu and Datroway hitting their peak revenue and rivals flowing into the antibody-drug conjugate space, Jefferies cuts expectations for Daiichi Sankyo.
  biospace · 2mo ago
• Earnings roundup: Biogen’s ‘resiliency,’ AstraZeneca’s growth pitch and GSK’s oncology push
  Better-than-expected sales helped Biogen regain the support of investors, while AstraZeneca and GSK worked to convince Wall Street that they can hit ambitious revenue targets.
  biopharma_dive · 2mo ago
• Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
  After keeping tight-lipped for nearly two years, Merck & Co. briefly dropped the first concrete hint as to where it intends to take its PD-1xVEGF bispecific antibody—before quietly scrubbing the ev…
  fiercebiotech · 2mo ago
• AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
  AstraZeneca executives told Fierce they are “very confident” in the pharma’s in-house pipeline of ADCs despite scrapping two candidates that underperformed in the clinic.
  fiercebiotech · 2mo ago